Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PACT-19

    • Most Recent Events

    • 24 Aug 2018 Results of the phase II part of the trial (n=54) published in the European Journal of Cancer
    • 12 Sep 2017 Final results from the phase II part, presented at the 42nd European Society for Medical Oncology Congress.
    • 31 Aug 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top